By Josh White
Date: Wednesday 18 Sep 2024
(Sharecast News) - London-based life science company ValiRx has announced that its wholly-owned subsidiary, Inaphaea BioLabs, has entered into an evaluation and commercial use agreement with Spanish contract research organisation Xenopat.
The AIM-traded firm said the agreement would involve the provision of Inaphaea's extensive collection of patient-derived cells (PDCs) for evaluation...
or login to read the full story
Email this article to a friend
or share it with one of these popular networks:
You are here: news